Dana-Farber Cancer Institute
J

Waldenström Macroglobulinemia: Diagnostic criteria, Why Not Treat Everybody at Diagnosis & Somatic Mutations in MYD88 and CXCR4

By Dana-Farber Cancer Institute FEATURING Jorge Castillo
By Dana-Farber Cancer Institute FEATURING Jorge Castillo
646 views
October 11, 2018
Comments 0
Login to view comments. Click here to Login

Featured Video

37:21
Amgen Sponsorship

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Recommended

AUTOPLAY
24:44

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

875 views
08:18

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

897 views
15:14

Safety Profile of Ruxolitinib in Patients With MF

Icahn School of Medicine at Mount Sinai

D. Tremblay

849 views
19:00

Waldenstrom’s Macroglobulinemia: Approaching the Newly Diagnosed and…

Indy Hematology Review

S. Treon

213 views
17:21

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

Daniel Addison

352 views
09:27

MAJIC-PV Trial: Ruxolitinib vs. Best Available Therapy for PV Intole…

ASH 2022 Conference Coverage

M. McMullin

1.1K views
06:51

Prevalence and Prediction of Ruxolitinib Treatment Emergent Thromboc…

Insights from 2023 ASH Annual Meeting

D. Tremblay

428 views
16:25

Diagnosis and Goals of Therapy in PV

Northwestern Medicine Oncology and Hematology

B. Stein

817 views
10:49

Using Cytoreductive Therapy to Prevent Cardiovascular Events in Pati…

Monia Marchetti

403 views
13:04

Treatment-Related Quality of Life in MF

Winship Cancer Institute - Emory University

A. Hunter

281 views
10:06

ASCO 2022 Bendamustine Rituximab vs. Ibrutinib as Primary Therapy fo…

ASCO 2022 Conference Coverage

J. Abeykoon

1.7K views
08:19

ASH 2022 Results From the Phase 1/2 BRUIN Study: Safety & Tolerabili…

ASH 2022 Conference Coverage

N. Shah

348 views
28:28

SOHO Italy 2023: How I Manage Waldenstrom’s Macroglobulinemia in the…

5th SOHO Italy Annual Conference

S. Treon

102 views
31:51

Managing Newly Diagnosed MM in 2023

Indy Hematology Review

S. Usmani

250 views
20:39

Emerging and Current Treatment of Waldenstrom’s Macroglobulinemia

Indy Hematology Review

S. Treon

60 views
03:42

ASCO® 2023 Insights: "BELLWAVE-003 - A Phase 2 Dose Escalation, Conf…

Insights from 2023 ASCO® Annual Meeting

G. Perini

190 views
11:11

ASH 2023 Insights: "Ibrutinib and Venetoclax in Symptomatic, Treatme…

Insights from 2023 ASH Annual Meeting

J. Castillo

117 views
24:53

Emerging and Current Treatment of Amyloidosis and Waldenstrom’s Macr…

Indy Hematology Review

M. Gertz

209 views
06:54

EHA 2024 Insights: CD20-Targeted CAR-T Therapy for BTKi-Refractory W…

Insights from 2024 EHA Annual Meeting

M. Shadman

61 views
03:40

ASCO® 2023 Insights: "Long-Term Safety With ≥12 Months of Pirtobruti…

Insights from 2023 ASCO® Annual Meeting

C. Coombs

105 views